Sign Up
Stories
Advancements in Immunotherapy for Neurological Disorders
Share
IVIg Offers Hope for 20-Year Remission i...
Sangamo Therapeutics' Gene Therapy Advan...
Takeda's HYQVIA Approved as CIDP Mainten...
Overview
API
Takeda receives positive CHMP opinion for HYQVIA® as maintenance therapy for CIDP, while Immusoft administers the first engineered B cell therapy in a clinical trial for MPS I. JCR Pharmaceuticals receives orphan drug designation for JR-441, and Immusoft successfully genetically engineers a patient's antibody cells to treat MPS I.
Ask a question
How might the successful engineering of a patient's antibody cells impact the future treatment of MPS I?
What are the broader implications of these advancements in immunotherapy for neurological disorders?
What are the potential implications of Takeda's positive CHMP opinion for the treatment of CIDP?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Dec 2023
Coverage